DiscoverTreating TogetherS6 Ep4: BMT CTN 1902 in Myeloma: Key Findings With Garfall
S6 Ep4: BMT CTN 1902 in Myeloma: Key Findings With Garfall

S6 Ep4: BMT CTN 1902 in Myeloma: Key Findings With Garfall

Update: 2025-03-13
Share

Description

In this episode of Targeted Talks, Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial (NCT05032820) of idecabtagene vicleucel (ide-cel; Abecma), a study focused on patients with multiple myeloma who had a suboptimal response to first-line therapy, including autologous hematopoietic cell transplant and lenalidomide (Revlimid) maintenance.






Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

S6 Ep4: BMT CTN 1902 in Myeloma: Key Findings With Garfall

S6 Ep4: BMT CTN 1902 in Myeloma: Key Findings With Garfall

Targeted Oncology